×
About 28,228 results

ALLMedicine™ Lymphomas Center

Research & Reviews  8,061 results

Lymphomatoid Papulosis "Type E" Affecting the Palate: A Detailed Case Report and Review...
https://doi.org/10.1097/DAD.0000000000002405
The American Journal of Dermatopathology; Silveira HA, Ragusa Silva PV et. al.

Mar 21st, 2023 - Lymphomatoid papulosis (LyP) belongs to the spectrum of primary cutaneous CD30+ lymphoproliferative disorders, characterized by chronic, recurrent, self-healing papules, small nodules, or ulcers. The clinicopathological features of LyP can mimic o...

Tracing founder mutations in circulating and tissue-resident follicular lymphoma precur...
https://doi.org/10.1158/2159-8290.CD-23-0111
Cancer Discovery; Schroers-Martin JG, Soo J et. al.

Mar 21st, 2023 - Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals suggesting additional lesions are required for lymphomagenesis. We directly cha...

Factors associated with survival in patients with lymphoma and HIV: the largest cohort ...
https://doi.org/10.1097/QAD.0000000000003549
AIDS (London, England); Vargas JC, Marques MO et. al.

Mar 21st, 2023 - To analyze the factors associated with survival in the largest cohort of individuals with HIV and lymphoma so far described in Brazil. A retrospective, observational, multicenter study involving five institutions in São Paulo, Brazil. The medical ...

Comparison of Primary B/NKT Non-Hodgkin Lymphomas in Nasopharynx, Nasal Cavity, and Par...
https://doi.org/10.1002/ohn.194
Otolaryngology--head and Neck Surgery : Official Journal ... Peng J, Qiu J et. al.

Mar 21st, 2023 - We aimed to compare clinical and survival differences between B-cell (B-NHL) and NKT-cell non-Hodgkin lymphomas (NKT-NHL) located in the nasal cavity (NC), nasopharynx, and paranasal sinuses, which are always categorized as one sinonasal type. Pat...

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma.
https://doi.org/10.1038/s41467-023-37216-2
Nature Communications; Portelinha A, da Silva Ferreira M et. al.

Mar 20th, 2023 - Spontaneous whole genome duplication and the adaptive mutations that disrupt genome integrity checkpoints are infrequent events in B cell lymphomas. This suggests that lymphomas might be vulnerable to therapeutics that acutely trigger genomic inst...

see more →

Guidelines  24 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and...
https://doi.org/10.1016/j.annonc.2019.10.010
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.

Jan 9th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Primary extranodal lymphoma of the glands. Literature review and options for best pract...
https://doi.org/10.1016/j.critrevonc.2019.01.005
Critical Reviews in Oncology/hematology; Belkacemi Y, Sio TT et. al.

Mar 2nd, 2019 - Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic opti...

see more →

Drugs  541 results see all →

Clinicaltrials.gov  896 results

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
https://clinicaltrials.gov/ct2/show/NCT05490771

Mar 13th, 2023 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
https://clinicaltrials.gov/ct2/show/NCT04195555

Mar 10th, 2023 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with AG-120 (ivosidenib) with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas...

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00001337

Mar 10th, 2023 - Background: The treatment of the intermediate and aggressive non-Hodgkin's lymphomas in adults and children commonly induces complete responses in a sizable fraction of the treated population, and about 2/3 of the complete responders appear to hav...

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
https://clinicaltrials.gov/ct2/show/NCT03213704

Mar 10th, 2023 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with larotrectinib sulfate (LOXO-101 [larotrectinib]) with advanced solid tumors (including central nervous sy...

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
https://clinicaltrials.gov/ct2/show/NCT03213678

Mar 10th, 2023 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with samotolisib (LY3023414) with advanced solid tumors, non-Hodgkin lymphomas or central nervous system (CNS)...

see more →

News  1,747 results

Jimmy Carter's Melanoma; Post-Op Osimertinib Boosts OS; $83K for Unproven Therapy
https://www.medpagetoday.com/hematologyoncology/skincancer/103467

Mar 9th, 2023 - How the successful use of pembrolizumab (Keytruda) for former President Jimmy Carter's metastatic melanoma put "immunotherapy on the map." (Washington Post) A study of molecular changes observed in the breast tissue of transgender men undergoing a...

Violaceous Nodules on the Leg in a Patient with HIV
https://www.mdedge.com/dermatology/article/261514/infectious-diseases/violaceous-nodules-leg-patient-hiv
Jessica Joanne Padniewski, DO, Shoshana Blumenthal, MD et. al.

Mar 1st, 2023 - The Diagnosis: Plasmablastic Lymphoma A punch biopsy of one of the leg nodules with hematoxylin and eosin staining revealed sheets of medium to large cells with plasmacytic differentiation (Figure, A and B). Immunohistochemistry showed CD79, epith.

The Evolving Role for Transplantation in Mantle Cell Lymphoma
https://www.mdedge.com/b-cell-lymphoma-icymi/article/261494/mantle-cell-lymphoma/evolving-role-transplantation-mantle-cell
Michael E. Williams, MD, ScM

Mar 1st, 2023 - Mantle cell lymphoma (MCL) has served as a paradigm of progress among the non-Hodgkin lymphomas over the past 30 years. It was originally defined within the Kiel classification as centrocytic lymphoma, then renamed MCL once the characteristic tran.

Woman Seeks Answers After 3 Years of Painful Genital Ulcers
https://www.medpagetoday.com/dermatology/generaldermatology/102873

Jan 30th, 2023 - A woman in her late 40s presented with painful ulcers in her groin and armpits that hadn't healed in 3 years, an Indian group reported in JAMA Dermatology. The woman explained that when the sores first appeared, they were just itchy, oozing, reddi...

MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies
https://www.medpagetoday.com/hematologyoncology/othercancers/102805

Jan 26th, 2023 - Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral murine double minute-2 (MDM2) inhibitor milademeta...

see more →

Patient Education  22 results see all →